Gyre Therapeutics (NASDAQ:GYRE) Shares Down 3.8% – Should You Sell?

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded down 3.8% during mid-day trading on Tuesday . The stock traded as low as $13.61 and last traded at $13.61. 1,520 shares were traded during trading, a decline of 98% from the average session volume of 69,687 shares. The stock had previously closed at $14.15.

Gyre Therapeutics Stock Down 0.6 %

The stock has a 50 day moving average price of $12.95 and a 200 day moving average price of $13.13.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $25.23 million for the quarter. On average, research analysts forecast that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in GYRE. Bank of New York Mellon Corp acquired a new position in Gyre Therapeutics in the second quarter worth approximately $218,000. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics during the 2nd quarter worth $123,000. WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics in the 2nd quarter worth $220,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics during the second quarter worth $166,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.